BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 179 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195 | +3.2% | 27,577 | +2.6% | 0.00% | 0.0% |
| Q2 2023 | $189 | +5.0% | 26,877 | +24.3% | 0.00% | 0.0% |
| Q1 2023 | $180 | -25.9% | 21,617 | +2.1% | 0.00% | 0.0% |
| Q4 2022 | $243 | -99.9% | 21,167 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $267,000 | +20.8% | 21,167 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $221,000 | -46.0% | 21,167 | -15.9% | 0.00% | -50.0% |
| Q1 2022 | $409,000 | +17.2% | 25,167 | 0.0% | 0.00% | +100.0% |
| Q4 2021 | $349,000 | -12.1% | 25,167 | -9.0% | 0.00% | -50.0% |
| Q3 2021 | $397,000 | -2.2% | 27,650 | +7.8% | 0.00% | 0.0% |
| Q2 2021 | $406,000 | +58.6% | 25,650 | +2.0% | 0.00% | +100.0% |
| Q1 2021 | $256,000 | +17.4% | 25,150 | -14.2% | 0.00% | 0.0% |
| Q4 2020 | $218,000 | +122.4% | 29,300 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $98,000 | -19.7% | 28,550 | +11.7% | 0.00% | 0.0% |
| Q2 2020 | $122,000 | +171.1% | 25,550 | +13.3% | 0.00% | – |
| Q1 2020 | $45,000 | -42.3% | 22,550 | -0.4% | 0.00% | -100.0% |
| Q4 2019 | $78,000 | +5.4% | 22,635 | -12.4% | 0.00% | 0.0% |
| Q3 2019 | $74,000 | -24.5% | 25,835 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $98,000 | -55.0% | 25,835 | -3.7% | 0.00% | -50.0% |
| Q1 2019 | $218,000 | -0.5% | 26,835 | -1.1% | 0.00% | 0.0% |
| Q4 2018 | $219,000 | -2.2% | 27,135 | -7.5% | 0.00% | 0.0% |
| Q3 2018 | $224,000 | +33.3% | 29,335 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $168,000 | +21.7% | 29,335 | +1.7% | 0.00% | +100.0% |
| Q1 2018 | $138,000 | -8.6% | 28,835 | -6.2% | 0.00% | -50.0% |
| Q4 2017 | $151,000 | -7.9% | 30,735 | -1.9% | 0.00% | 0.0% |
| Q3 2017 | $164,000 | -11.4% | 31,335 | -6.0% | 0.00% | 0.0% |
| Q2 2017 | $185,000 | -30.7% | 33,335 | +4.7% | 0.00% | -50.0% |
| Q1 2017 | $267,000 | +32.2% | 31,835 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $202,000 | +38.4% | 31,835 | -4.1% | 0.00% | 0.0% |
| Q3 2016 | $146,000 | +100.0% | 33,185 | +29.2% | 0.00% | +50.0% |
| Q1 2016 | $73,000 | -72.8% | 25,685 | -1.0% | 0.00% | -71.4% |
| Q4 2015 | $268,000 | +24.1% | 25,935 | +36.6% | 0.01% | +16.7% |
| Q3 2015 | $216,000 | -99.9% | 18,985 | +10.8% | 0.01% | +20.0% |
| Q2 2015 | $255,826,000 | +211326.4% | 17,135 | +27.9% | 0.01% | +150.0% |
| Q1 2015 | $121,000 | -99.9% | 13,400 | +2.7% | 0.00% | -33.3% |
| Q4 2014 | $158,688,000 | +24.3% | 13,050 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $127,629,000 | -23.3% | 13,050 | 0.0% | 0.00% | -25.0% |
| Q2 2014 | $166,388,000 | +20.5% | 13,050 | 0.0% | 0.00% | +33.3% |
| Q1 2014 | $138,069,000 | +61.5% | 13,050 | +16.0% | 0.00% | +50.0% |
| Q4 2013 | $85,500,000 | – | 11,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |